Brief Report: Post Hoc Validation of Platinum Ineligibility in NSCLC From the Phase III IPSOS Study

INTRODUCTION: The Phase III IPSOS study (NCT03191786) demonstrated that atezolizumab was associated with improved survival, stable patient-reported outcomes and a favorable safety profile vs single-agent chemotherapy in patients with NSCLC ineligible for platinum-based chemotherapy. As no established consensus criteria for platinum ineligibility exist for NSCLC, we performed a post hoc analysis from IPSOS to evaluate clinical outcomes in a selected platinum-ineligible (sPI) population meeting a refined definition. METHODS: Patients with stage IIIB/IV NSCLC who were ineligible for platinum-doublet chemotherapy were randomized (2:1) to receive atezolizumab or single-agent chemotherapy (vinorelbine or gemcitabine). Patients in the sPI subgroup were defined as those with either ECOG PS 3, age >80 years, ECOG PS 2 with relevant comorbidities, or age

• Peters, S.
• Schulz, C.
• Reck, M.
• Prabhash, K.
• Kowalski, D.
• Szczesna, A.
• Han, B.
• Rittmeyer, A.
• Talbot, T.
• Vicente, D.
• Califano, R.
• Cortinovis, D.
• Le, A. T.
• Huang, D.
• Liu, G.
• Cappuzzo, F.
• Contreras, J. R.
• Palmero, R.
• Mak, M. P.
• Popat, S.
• Hu, Y.
• Morris, S.
• Srivastava, M. K.
• Kaul, M.
• Graupner, V.
• Gitlitz, B.
• Lee, S. M.